• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjects

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Results of the phase Ib dose escalation study of MEN1611, a PI3K inhibitor, combined with trastuzumab (T) +/- fulvestrant (F) for HER2+/PIK3CA mutant (mut) advanced or metastatic (a/m) breast cancer (BC)

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Thumbnail
    Name:
    Results.pdf
    Size:
    91.04Kb
    Format:
    PDF
    Description:
    From UNPAYWALL
    Download
    Authors
    Piccart, M.
    Borrego, M. R.
    Duhoux, F.
    Arkenau, H. T.
    de Speville, B. D.
    Wildiers, H.
    Campone, M.
    Tosi, D.
    Garcia-Corbacho, J.
    Jimenez, B.
    Escriva-de Romani, S.
    Wardley, Andrew M
    Tassone, P.
    Boni, V.
    Jerez, Y.
    Aftimos, P. G.
    Hennequin, A.
    Amair-Pinedo, F.
    Pellacani, A. U. E.
    Laurent, D. O.
    Show allShow less
    Affiliation
    Medical Oncology Clinic, Institut Jules Bordet-Université Libre de Bruxelles, Brussels, Belgium;
    Issue Date
    2020
    
    Metadata
    Show full item record
    Abstract
    Background: MEN1611 (MEN) is an oral PI3K inhibitor active on the p110a mut and WT, b and g isoforms, while sparing the d. Antitumor activity of MEN combined with other agents in patient-derived xenografts and BC cell lines with different PIK3CA mutations, provides a strong rationale for clinical testing. Methods: B-PRECISE-01 is an ongoing phase Ib study in patients (pts) with HER2+/ PIK3CAmut a/m BC treated with at least 2 anti-HER2 therapies. A 3+3 design combined 3 dose levels of MEN BID and T weekly IV. HR+ postmenopausal pts also received F. Primary objectives are to determine safety and recommended phase II dose (RP2D). Dose-limiting toxicities (DLTs) were assessed during cycle 1. Secondary objectives included assessment of preliminary clinical activity, pharmacokinetics and pharmacodynamics. Here we present mature data from dose escalation cohorts. Results: As of Oct. 2019, 12 female pts were treated: 9 MEN+T+F and 3 MEN+T. Median age: 59 years (range 39-77). Median prior metastatic regimens: 5.5 (4-12). No DLTs were observed at any dose cohort. 48 mg was selected as RP2D. Most common grade (G)1/2 treatment-related adverse events (TRAEs) were diarrhoea (n¼9), anemia (n¼6), nausea (n¼4), asthenia (n¼4), decreased appetite (n¼4), hyperglycemia (n¼4), and mucosal inflammation (n¼3). G3/4 TRAEs were not dose-dependent and occurred in 4 pts such as hyperglycemia (n¼3), pneumonitis (n¼1), decreased appetite (n¼1), mucosal inflammation (n¼1), and AST/ALT increase (n¼1). Dose was reduced in one pt at 48 mg. No deaths from toxicity occurred. There were no overt differences in the safety profile of MEN+T+F vs. MEN+T. 5 pts (42%) had partial response, 5 stable disease, 4 disease control >8 months (mo) and 2 were on treatment >11 mo. MEN exposure tends to increase with increasing doses. Tmax was reached after 0.5-8 h following administration and the terminal half-life was w3.5 h. Conclusions: Tolerability of MEN+T F is acceptable; most TRAEs were reversible and manageable by supportive care. Promising antitumor activity in heavily pretreated pts, together with prolonged disease control, provide the rationale for cohort expansion at RP2D in pts with HER2+/PIK3CA mut a/m BC.
    Citation
    Piccart M, Borrego MR, Duhoux F, Arkenau HT, Doger de Spéville B, Wildiers H, et al. 347P Results of the phase Ib dose escalation study of MEN1611, a PI3K inhibitor, combined with trastuzumab (T) ± fulvestrant (F) for HER2+/PIK3CA mutant (mut) advanced or metastatic (a/m) breast cancer (BC). Annals of Oncology. 2020;31:S386-S.
    Journal
    Annals of Oncology
    URI
    http://hdl.handle.net/10541/623483
    DOI
    10.1016/j.annonc.2020.08.449
    Additional Links
    https://dx.doi.org/10.1016/j.annonc.2020.08.449
    Type
    Meetings and Proceedings
    Language
    en
    ae974a485f413a2113503eed53cd6c53
    10.1016/j.annonc.2020.08.449
    Scopus Count
    Collections
    All Christie Publications

    entitlement

     
    DSpace software (copyright © 2002 - 2021)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.